Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.

I Kuiatse, V Baladandayuthapani, H Lin, S Thomas, C Bjorklund, D Weber, M Wang, J Shah, X Zhang, R Jones, S Ansell, G YANG, R ORLOWSKI

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalClinical Cancer Research.
Volume21(11):2538-45
StatePublished - Jan 1 2015

Cite this

Kuiatse, I., Baladandayuthapani, V., Lin, H., Thomas, S., Bjorklund, C., Weber, D., Wang, M., Shah, J., Zhang, X., Jones, R., Ansell, S., YANG, G., & ORLOWSKI, R. (2015). Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia. Clinical Cancer Research., 21(11):2538-45.